Overview

Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes

Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
To investigate the safety and tolerance after allogeneic infusion of WJMSCs intravenously in adult patients diagnosed with type 1 diabetes.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
NextCell Pharma Ab